Dear Editor: With reference to the recent article on maternal exposure to angiotensin II receptor antagonist, 1 we take issue with the authors' statement that fetal complications ensued drug exposure during the first part of gestation.
RESPONSE
We appreciated the comments of Dr Chow and Lam regarding to our case report of acute neonatal renal failure following exposure to telmisartan, angiotensin receptor II inhibitor (ARAII). We agree with them considering toxicity during the last part of gestation. In the discussion, we said that the fetal toxicity of ARAII occurs when fetal exposure hold during the first part of gestation. Different case reports published in the literature [1] [2] [3] showed exposure to ARAII at 24, 28 and 34th weeks and between the 17th and 31st weeks. First part of gestation in our mind was opposed to last trimester. The duration of drug exposure in our case didn't seem to be a relevant prognosis criteria. Hinsberger reported another case with favorable outcome with drug exposure from the beginning to the end of gestation. A critical period of fetal exposure is probably a determinant for renal toxicity as demonstrated in the different cases of the literature. Genetics and amount of drugs are other possible explanations of toxicity. In conclusion, this drug should be avoided during pregnancy.
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